Evidence map›Paper›PMID 30324554›Full record

ArticleDigestive diseases and sciences2019

Declining Rates of Referral for Irritable Bowel Syndrome Without Constipation at a Tertiary Care Center.

Sun Jung Oh, Vartan C Tashjian, James Mirocha, Menachem Nagar, Ruchi Mathur, Eugenia Lin, Kathleen Shari Chua, Ali Rezaie, Mark Pimentel, Nipaporn Pichetshote

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sun Jung OhDivision of General Internal Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Vartan C TashjianDivision of General Internal Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
James MirochaBiostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Menachem NagarGI Motility Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Ruchi MathurDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Eugenia LinGI Motility Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Kathleen Shari ChuaMedically Associated Science and Technology (MAST) Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ali RezaieGI Motility Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Mark PimentelGI Motility Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Nipaporn PichetshoteGI Motility Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. Nipaporn.Pichetshote@cshs.org.ORCID http://orcid.org/0000-0002-2186-6984
Cedars-Sinai Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIrritable bowel syndrome (IBS) is a common chronic disorder of the gastrointestinal tract. Several treatments have been developed, including rifaximin for the treatment of IBS without constipation (non-IBS-C), but no studies have evaluated the effect of these therapies on patient referral rates to tertiary care gastroenterology clinics.

aimTo assess referral patterns for IBS patients at a tertiary motility clinic over a 10-year period.

methodsData from consecutive patients referred to the clinic during 2006-2016 were analyzed. Trends in the proportion of referrals and prior rifaximin use in IBS-C versus non-IBS-C groups were compared.

resultsA total of 814 adult patients were referred to a single physician panel for IBS-related symptoms. Of these, 776 were included in the study [528 females (68%), average age 45.7 ± 15.9 years), comprising 431 IBS-C (55.5%) and 345 non-IBS-C (44.5%) patients. The proportion of non-IBS-C referrals declined significantly from 53.0% in 2006 to 27.3% in 2016 (Chi-square, p < 0.0001, Cochran-Armitage trend test p = 0.0001), and the proportion of IBS-C referrals increased significantly from 46.9% in 2006 to 72.7% in 2016 (Chi-square, p < 0.0001, Cochran-Armitage trend test p = 0.0004). Non-IBS-C referrals with prior rifaximin use significantly increased from 22.7% in 2006 to 66.7% in 2016 (Cochran-Armitage trend test, p = 0.008).

conclusionsThe results indicate a significantly declining tertiary care referral rate for non-IBS-C over the past decade. While not directly linked, there has been an increase in rifaximin use in the same population during the same time interval.

Indexed as

AdultAgedDrug Utilization ReviewFemaleGastrointestinal AgentsHumansIrritable Bowel SyndromeLos AngelesMaleMiddle AgedPractice Patterns, Physicians'Referral and ConsultationRetrospective StudiesRifaximinTertiary Care CentersTime FactorsGastrointestinal AgentsRifaximinConstipationDiarrheaIrritable bowel syndromeReferral ratesRifaximin

Identifiers

PMID30324554
OpenAlexW2897686257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.